For the past 7 years, pharmaceuticals that work as glucagon-like peptide 1 (GLP-1) receptor agonists have dominated the weight-loss and diabetes markets. These drugs, currently so ...
Cancer is becoming increasingly common among young people, with cases slowly and steadily rising every year for the past ...